SCHEMBL20401232

SCHEMBL20401232

O=c1[nH]ncc2cc(NCc3ccc(C4CCCCC4)cc3)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.46
PRMT5 O14744 1/20 0.44
WDR77 Q9BQA1 1/20 0.44
ROCK2 O75116 2/20 0.43
INSR P06213 1/20 0.38
IGF1R P08069 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
KDR P35968 1/20 0.38
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37
ROCK1 Q13464 1/20 0.37
PRKG1 Q13976 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
USP1 O94782 2/20 0.37
WDR48 Q8TAF3 2/20 0.37
PDE9A O76083 2/20 0.36
MAPT P10636 2/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20401426 0.82 ROCK2 (0.47) STAT3PRMT5WDR77ROCK2HTR2C
SCHEMBL2461071 0.77 ROCK2 (0.59) ROCK2GSK3AGSK3BROCK1PRKG1
SCHEMBL15586969 0.74 ALDH1A1 (0.50) STAT3PRMT5WDR77ROCK2HRH3
SCHEMBL12326069 0.73 PRMT5 (0.52) STAT3PRMT5WDR77MAPTGAA
SCHEMBL11513059 0.70 HTR2C (0.40) HRH3HTR2CHTR2BKDRUSP1
SCHEMBL11513083 0.68 AGER (0.54) HRH3HTR2CHTR2BKDRMAPT
SCHEMBL11509341 0.68 MAPT (0.54) HRH3HTR2CHTR2BMAPTGAA
SCHEMBL11512084 0.68 HSD11B1 (0.49) HRH3HTR2CHTR2BKDRUSP1
SCHEMBL11511592 0.68 DEGS1 (0.55) HTR2CHTR2BKDRMAPTGAA
SCHEMBL11936043 0.68 EPHX1 (0.44) HRH3HTR2CHTR2BKDRUSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11299480-B2 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors UNIVERSITY OF HAWAII (US) 2022-04-12 US disclosed
WO-2018136935-A1 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS UNIVERSITY OF HAWAII (US) 2018-07-26 WO disclosed
WO-2018136935-A1 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS UNIVERSITY OF HAWAII (US) 2018-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11299480-B2 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors STAT3, JAK2, STAT5A STAT3 1/4885PRMT5 1502/4885WDR77 3587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.